Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease - PubMed (original) (raw)

Multicenter Study

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Kenneth I Zheng et al. Metabolism. 2020 Jul.

No abstract available

Keywords: COVID-19; MAFLD; Obesity; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors declare no conflict of interests.

Comment in

• Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
  Hussain A, Vasas P, El-Hasani S. Hussain A, et al. Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29. Metabolism. 2020. PMID: 32360211 Free PMC article. No abstract available.

Similar articles

• Commentary: Obesity: The "Achilles heel" for COVID-19?
  Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Muscogiuri G, et al. Metabolism. 2020 Jul;108:154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27. Metabolism. 2020. PMID: 32353356 Free PMC article. No abstract available.
• Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
  Hussain A, Vasas P, El-Hasani S. Hussain A, et al. Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29. Metabolism. 2020. PMID: 32360211 Free PMC article. No abstract available.
• Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
  Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Ji D, et al. J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278005 Free PMC article. No abstract available.
• Obesity and impaired metabolic health in patients with COVID-19.
  Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Stefan N, et al. Nat Rev Endocrinol. 2020 Jul;16(7):341-342. doi: 10.1038/s41574-020-0364-6. Nat Rev Endocrinol. 2020. PMID: 32327737 Free PMC article. Review.
• Will the COVID-19 pandemic worsen the obesity epidemic?
  Clemmensen C, Petersen MB, Sørensen TIA. Clemmensen C, et al. Nat Rev Endocrinol. 2020 Sep;16(9):469-470. doi: 10.1038/s41574-020-0387-z. Nat Rev Endocrinol. 2020. PMID: 32641837 Free PMC article. Review.

Cited by

• Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives.
  Dalamaga M, Christodoulatos GS, Karampela I, Vallianou N, Apovian CM. Dalamaga M, et al. Curr Obes Rep. 2021 Sep;10(3):214-243. doi: 10.1007/s13679-021-00436-y. Epub 2021 Apr 28. Curr Obes Rep. 2021. PMID: 33909265 Free PMC article. Review.
• Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.
  Sharma P, Kumar A. Sharma P, et al. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):825-827. doi: 10.1016/j.dsx.2020.06.013. Epub 2020 Jun 10. Diabetes Metab Syndr. 2020. PMID: 32540736 Free PMC article.
• Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.
  Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, Kario K, Kishi T, Mogi M, Nishiyama A, Ohishi M, Ohkubo T, Tamura K, Tanaka M, Yamamoto E, Yamamoto K, Itoh H. Shibata S, et al. Hypertens Res. 2020 Oct;43(10):1028-1046. doi: 10.1038/s41440-020-0515-0. Epub 2020 Jul 31. Hypertens Res. 2020. PMID: 32737423 Free PMC article. Review.
• The Impact of Sociodemographic, Nutritional, and Health Factors on the Incidence and Complications of COVID-19 in Egypt: A Cross-Sectional Study.
  Schaalan M, Abou Warda AE, Osman SM, Fathy S, Sarhan RM, Boshra MS, Sarhan N, Gaber S, Ali AMA. Schaalan M, et al. Viruses. 2022 Feb 22;14(3):448. doi: 10.3390/v14030448. Viruses. 2022. PMID: 35336855 Free PMC article.
• The COVID-19, Obesity, and Food Insecurity Syndemic.
  Pryor S, Dietz W. Pryor S, et al. Curr Obes Rep. 2022 Sep;11(3):70-79. doi: 10.1007/s13679-021-00462-w. Epub 2022 Feb 9. Curr Obes Rep. 2022. PMID: 35138590 Free PMC article. Review.

References

1. 1. WHO characterizes COVID-19 as a pandemic. March 13, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-a...
2. 1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. In press. - DOI - PMC - PubMed
3. 1. Eslam M., Newsome P.N., Anstee Q.M., Targher G., Gomez M.R., Zelber-Sagi S., et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
4. 1. Arias-Loste M.T., Fábrega E., López-Hoyos M., Crespo J. The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease. Biomed Res Int. 2015;2015:319745. - PMC - PubMed
5. 1. Lee C.H., Choi S.H., Chung G.E., Park B., Kwak M.S. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018;38:2091–2100. - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal